Lonza expands its GMP solutions for cell and gene therapy
The newly-added solutions provide researchers and manufacturers with high-performance, scalable, and regulatory-ready solutions that streamline cell and gene therapy workflows from discovery through clinical development
17 Oct 2025
AmpliCell® Cytokine Range and TheraPEAK® 293-GT® Medium
Lonza has launched TheraPEAK® AmpliCell® Cytokines and TheraPEAK® 293-GT® Medium to expand its GMP solutions for cell and gene therapy.
AmpliCell® Cytokines enable cell expansion optimization, batch-to-batch consistency and easy transition from research to manufacturing. TheraPEAK® 293-GT® Medium System aims to help accelerate development timelines and improve consistency from research through to GMP gene therapy production.
Cytokines represent a critical component in cell therapy manufacturing, supporting the expansion and maintenance of living cells. TheraPEAK® AmpliCell® Cytokines enable the reliable expansion, activation, and differentiation of immune cells.
Produced in a mammalian expression system and engineered for high biological activity, these cytokines feature proper folding and glycosylation, delivering native-like structure and function that bacterial systems cannot match. This ensures superior biological relevance, batch-to-batch consistency, and greater predictability in sensitive and translational applications, both in research and GMP set-ups.
TheraPEAK® 293-GT® Medium is a chemically defined, animal–origin–free system optimized for adeno-associated virus (AAV) production in suspension HEK293 cells, providing a reliable, scalable option for advancing gene therapy programs. Unlike off-the-shelf viral production kits that may lack flexibility, the 293-GT® System (growth medium plus supplement) is a drop-in-ready solution engineered to integrate seamlessly with existing workflows.
The media is compatible with commercially available transfection reagents and AAV enhancers, delivers strong AAV titers, and supports high full-to-empty capsid ratios.
Mike Goetter, Head of Bioscience, Specialized Modalities, Lonza, said, “The introduction of AmpliCell® Cytokines and the 293-GT® Medium to our TheraPEAK® Range greatly enhances our offering for cell and gene therapy customers, providing them with reliable solutions to support their drug development efforts.”